Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirsevimab for RSV prevention in infants
NCT05437510Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2022
- Primary completion
- Mar 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of nirsevimab in respiratory syncytial virus infection (RSV), sponsored by Sanofi. Started Aug 2022; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05437510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437510.